HOME Research Insight Product and Service Launches and Agreements, Partnerships, and Collaborations Were the Key Growth Strategies Adopted by Leading Market Players in the Global Next-generation Sequencing Market



Product and Service Launches and Agreements, Partnerships, and Collaborations Were the Key Growth Strategies Adopted by Leading Market Players in the Global Next-generation Sequencing Market


The global next-generation sequencing (NGS) market is expected to grow at a CAGR of 20.5% between 2017 and 2022. The factors driving the growth of this market are technological advancements in NGS platforms, increasing applications of NGS, growing partnerships and collaborations, and increasing adoption of NGS in research laboratories and academic institutes. However, accuracy and standardization concerns in diagnostic testing and the lack of skilled technical personnel are some of the key factors limiting the growth of the market.

Illumina market revenues will be driven by the SBS technology platforms which are in high demand due to wide applications and its usage for both single read and pair end libraries.

In the next-generation sequencing market, companies focus on the strategy of new product launches to grow; this strategy accounted for half of the total number of growth strategies. Driven by advanced research and engineering activities, innovation in existing technologies, curiosity for a vast range of innovative platforms, and increased demand for highly compatible all-inclusive solutions have forced companies to focus on product launches. This strategy was adopted by players to provide high performance and robust technologies for sequencing to ensure explorative genomic research. It was also implemented to unlock novel diverse applications with the use of a single platform. The significant players adopting this strategy include Illumina, Inc (U.S.), Thermo Fisher Scientific (U.S.), Agilent Technologies, Inc (U.S.), Pacific Biosciences (U.S.), DNASTAR, INC (U.S.), 454 Life Sciences Corporation (U.S.), PerkinElmer, Inc (U.S.), GATC Biotech AG (Germany) and CLC bio (a member of QIAGEN). For example, in January 2014, Illumina unveiled two new sequencing platforms—the HiSeq X Ten sequencing system to study genotypic variations in a human population and the NextSeq 500 sequencing system that offers high-throughput performance in an affordable desktop form. NextSeq 500 will enable researchers to perform the most popular sequencing applications in less than a day. These new launches helped to expand the company’s sequencing product line. Illumina also launched multiple sequencing panels for cancer research which is the major focus of research currently.

Related Reports:

Next Generation Sequencing (NGS) Market by Platforms (Illumina HiSeq, MiSeq, HiSeqX Ten, NextSeq 500,Thermo Fisher Ion Proton/PGM), Bioinformatics (Exome Sequencing, RNA-Seq, ChIP-Seq), Technology (SBS, SMRT) & by Application (Diagnostics, Personalized Medicine) – Global Forecast to 2020

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports